|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date01 May 2012 |
/ SuspendedNot ApplicableIIT Effect of azelastine fluticasone nasal spray on nasal function and symptoms of moderate to severe allergic rhinitis
Start Date13 Mar 2025 |
Sponsor / Collaborator- |
Efficacy of As-needed versus Regular Use of MP-AzeFlu in Moderate-to-severe Allergic Rhinitis: A randomized controlled trial
Start Date01 Dec 2023 |
Sponsor / Collaborator- |
Single Dose Bioequivalence Study of Azelastine Hydrochloride/Fluticasone Propionate 137microgram/50 Microgram Nasal Spray and DYMISTA Nasal Spray in Healthy Adult Human Subjects
Single dose (four sprays) bioequivalence study of Azelastine Hydrochloride/ Fluticasone Propionate 137 microgram/50 microgram Nasal Spray and 'DYMISTA' (Azelastine Hydrochloride/Fluticasone Propionate) Nasal Spray 137 microgram/50 microgram in healthy adult human subjects.
Start Date24 Mar 2023 |
Sponsor / Collaborator- |
100 Clinical Results associated with cPLA2α x H1 receptor x GR
100 Translational Medicine associated with cPLA2α x H1 receptor x GR
0 Patents (Medical) associated with cPLA2α x H1 receptor x GR